Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 15, 2014; 5(3): 399-406
Published online Jun 15, 2014. doi: 10.4239/wjd.v5.i3.399
Published online Jun 15, 2014. doi: 10.4239/wjd.v5.i3.399
Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data
Jagriti Bhatia, Nanda Gamad, Saurabh Bharti, Dharamvir Singh Arya, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi-110029, India
Author contributions: All the authors contributed in collection of data on CFZ; Bhatia J and Gamad N were involved in writing the manuscript; Gamad N and Bharti S compiled the table no. 1 (Summary of clinical trials of CFZ) and table no. 2 (Summary of adverse events observed in the CFZ clinical trials) in the manuscript; Arya DS did the final editing of the review article.
Correspondence to: Dr. Jagriti Bhatia, Department of Pharmacology, All India Institute of Medical Sciences, Gautam Nagar, New Delhi-110029, India. jagriti2012@gmail.com
Telephone: +91-11-26594266 Fax: +91-11-26584121
Received: January 22, 2014
Revised: April 3, 2014
Accepted: April 17, 2014
Published online: June 15, 2014
Processing time: 145 Days and 12.8 Hours
Revised: April 3, 2014
Accepted: April 17, 2014
Published online: June 15, 2014
Processing time: 145 Days and 12.8 Hours
Core Tip
Core tip: This review article focuses upon the current pharmacokinetic, pharmacodynamic and clinical trial data on the newly introduced sodium-glucose co-transporter 2 inhibitor, canagliflozin, for the treatment of type 2 diabetes mellitus. It also discusses briefly about the safety profile and future prospective of canagliflozin.